AVITA Medical, Inc. (RCEL) stock
RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
$15.63−0.57 (-3.52%)
Close on Nov 13, 2026Market cap $483.39MP/E –Yield –
AVITA Medical r&d expenses
Research and development expenses are spending on new products and technology.
AVITA Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $21.10M, up 5.5% year over year. For fiscal 2025 it was $20.84M, up 2.4% from the year before. The highest annual figure on record is $20.84M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.84M | +2.4% |
| FY2024 | Dec 31, 2024 | $20.36M | -2.2% |
| FY2023 | Dec 31, 2023 | $20.82M | +40.5% |
| FY2021 | Jun 30, 2021 | $14.82M | +61.7% |
| FY2020 | Jun 30, 2020 | $9.16M | +14.5% |
| FY2019 | Jun 30, 2019 | $8.00M | +27.9% |
| FY2018 | Jun 30, 2018 | $6.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $4.70M | +25.3% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $5.08M | -0.8% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $5.63M | -10.4% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $5.69M | +17.3% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $3.75M | -31.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $5.12M | +4.7% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $6.28M | +21.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $4.85M | -28.3% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $5.43M | +23.5% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $4.89M | -3.7% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $5.19M | +13.3% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $6.77M | +70.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $4.39M | +6.9% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $5.08M | +51.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $4.59M | +35.9% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $3.97M | +56.6% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $4.11M | +64.7% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $3.36M | +45.4% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $3.37M | +85.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $2.54M | +22.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $2.50M | +37.9% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $2.31M | +14.5% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $1.82M | -7.8% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $2.07M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.81M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $2.02M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.97M | – |
See a number that looks wrong?